Company news
ProMIS Neurosciences Inc. news in 2023
ProMIS Neurosciences Inc.'s news releases, calls and decks from 2023, newest first.
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 19, 2023
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 19, 2023
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 13, 2023
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 7, 2023
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 5, 2023
Satellos Expands Leadership Team with New CFO Appointment
September 4, 2023
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
August 20, 2023
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
August 13, 2023
ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
July 16, 2023
ProMIS Announces Completion of Continuance
July 13, 2023
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
July 9, 2023
ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved
June 29, 2023
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9: 30am Eastern Time
June 28, 2023
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
May 14, 2023
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
May 7, 2023
Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease
April 24, 2023
ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting
April 23, 2023
ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310
April 9, 2023
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023
March 28, 2023
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023
March 12, 2023
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting
March 12, 2023
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights
March 7, 2023